Company: SCLXW
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001193125-25-221022
Chunk: 122

Company: Scilex Holding Co
Filing Date: 2025-09-29
Form: 424B3
Chunk 122
---
 provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech,
real estate, healthcare, energy and more. The Information Data Exchange (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world
objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and
data, marketing automation and advertising monitoring.

The company is headquartered in Beaverton, OR.

Learn more about Datavault AI at www.dvlt.ai

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-

Page | 3

looking statements include, but are not limited to, statements regarding future events, Scilex’s proposed investment in Datavault, timing thereof and anticipated use of bitcoin proceeds as
growth capital for Datavault’s expansion plans, the market size of the biotech data monetization market, Scilex’s plans to create a potential marketplace for RWA in the biotech and pharmaceutical industry, Scilex’s plans to appoint
directors to the Datavault board, potential Datavault stockholder approval, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the
current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and
its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not
historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only